INTRODUCTION
============

Recent changes in American and European guidelines on the management of arterial hypertension have caused a considerable shift in the landscape of hypertension management \[[@b1-kjim-2018-382],[@b2-kjim-2018-382]\]. The 2017 American College of Cardiology/American Heart Association/American Society of Hypertension guideline recommends a new threshold for diagnosis of hypertension, i.e., an office visit blood pressure (BP) \> 130/80 mmHg, and states that the treatment goal for all hypertensive patients should be lowered to \< 130/80 mmHg \[[@b1-kjim-2018-382]\]. In addition, the new American guideline recommends that drug treatment should be considered in high-risk patients with stage 1 hypertension, and in those with BPs in the range of 130/80 to 140/90 mmHg and an arteriosclerotic vascular disease risk score of \> 10% or cardiovascular disease (CVD) \[[@b1-kjim-2018-382]\]. In contrast, the new 2018 European guideline maintains the diagnostic threshold of hypertension at 140/90 mmHg \[[@b2-kjim-2018-382]\]. However, the European guideline recommends a strict target systolic blood pressure (SBP) goal of ≤ 130 mmHg for most hypertensive patients, with the exception of those with chronic kidney disease (CKD) or advanced age (\> 65 years); furthermore, the diastolic blood pressure (DBP) should be controlled in the range of 70 to 80 mmHg \[[@b2-kjim-2018-382]\]. In addition, the new European guideline suggests that drug treatment should be considered in patients with BPs in the range of 130 to 139/85 to 89 mmHg who are at high cardiovascular risk due to established CVD \[[@b2-kjim-2018-382]\]. Therefore, despite their differences in threshold for diagnosis of hypertension, both guidelines are in agreement that treatment should be considered in patients with BPs in the range of 130 to 139/80 to 89 mmHg if they have high cardiovascular risk. Here, we discuss the evidence for drug treatment in this subset of patients, and the potential benefits and harms associated with antihypertensive treatment.

REDEFINING THE THRESHOLD OF HYPERTENSION
========================================

The differences in American and European guidelines regarding the BP threshold of hypertension stem from their differing definitions of hypertension. The American definition of hypertension is based on epidemiologic studies that convincingly show increased cardiovascular risk with increasing BP; compared to those with a BP of 115/75 mmHg, each increase in SBP/DBP of 20/10 mmHg is associated with double the risk of death from stroke or coronary artery disease (CAD) \[[@b1-kjim-2018-382],[@b3-kjim-2018-382]\]. Additionally, meta-analyses of observational studies show a 1.5- and 2-fold higher risk of coronary heart disease and stroke, respectively, in subjects with BP 130 to 139/85 to 89 mmHg compared to those with BP \< 120/80 mmHg \[[@b1-kjim-2018-382],[@b4-kjim-2018-382]-[@b6-kjim-2018-382]\]. A recent analysis of the Korea Acute Myocardial Infarction Registry revealed significant elevation of the odds ratio (OR) for 6-month major adverse cardiovascular events (MACE) in emergency department patients with high-normal BP and acute myocardial infarction (OR, 1.147; 95% confidence interval \[CI\], 1.011 to 1.402; p = 0.045) compared to patients with normal BP \[[@b7-kjim-2018-382]\].

The American guideline defines hypertension as the BP threshold, above which the CVD risk is significantly increased compared to that associated with normal BP (130/80 mmHg) \[[@b1-kjim-2018-382]\]. In contrast, the European guideline defines hypertension as the level of BP, above which the benefits of treatment (either with lifestyle interventions or drug treatment) clearly outweigh the risks of treatment \[[@b2-kjim-2018-382]\]. Irrespective of the American or European definitions of hypertension, due to the high prevalence of prehypertension in the general population, lowering the threshold of hypertension would result in marked elevation in the prevalence of hypertension and an unnecessary increase in the risk of labeling a large portion of the population with a disease that they may not actually have \[[@b8-kjim-2018-382],[@b9-kjim-2018-382]\].

Prior to the Systolic Blood Pressure Intervention Trial (SPRINT) study, no trials used the SBP inclusion criteria of ≥ 130 mmHg to investigate whether further lowering of BP would result in reduced cardiovascular risk \[[@b10-kjim-2018-382]\]. However, the inclusion criteria and BP measurement methods used in the SPRINT trial suggest that the study did not actually include treatment-naïve patients with SBP \> 130 mmHg \[[@b10-kjim-2018-382]\]. First, the majority of the patients enrolled in the SPRINT study were treated hypertensive patients, and only 2.7% of the patients in the intensive treatment arm and 11.3% in the standard treatment arm were considered treatment-naïve at randomization. As such, if these patients had been washed out from their medications, they would likely have had BP \> 140/90 mmHg. Second, the SPRINT study used unattended automatic office blood pressure (AOBP) measurement for the office BP measurement. As studies have shown that AOBP is 5 to 15 mmHg lower than manual office BP measurements, AOBP SBP of 130 mmHg would have most likely corresponded to the manual office SBP of 140 mmHg, which would not differ from the previous definition of hypertension \[[@b2-kjim-2018-382],[@b11-kjim-2018-382]\].

The criteria for hypertension differ depending on whether the American or European guideline definition of hypertension is used. Another important and controversial topic is whether these subjects should be treated with antihypertensive medications. The lines of evidence that support and dispute these recommendations are presented below.

PROS AND CONS OF MEDICAL TREATMENT OF SUBJECTS WITH SBP BETWEEN 130--139 MMHG
=============================================================================

The benefit of BP lowering treatment in patients with hypertension is indisputable. In a recent meta-analysis of 123 studies including 613,815 participants, Ettehad et al. \[[@b12-kjim-2018-382]\] demonstrated that each 10 mmHg reduction in SBP is associated with a 20% reduction in the risk of major cardiovascular events, 17% reduction in the risk of coronary heart disease, 27% reduction in the risk of stroke, 28% reduction in the risk of heart failure, and 13% reduction in all-cause mortality. However, an unanswered question is whether BP lowering with anti-hypertensive treatment improves the outcome in patients with high-normal BP, defined as SBP between 130 to 139 mmHg. The most compelling evidence regarding the need to treat patients with SBP above 130 mmHg was provided by the SPRINT study, in which high-risk individuals with BP \> 130 mmHg were randomized to a target SBP of 120 or 140 mmHg \[[@b10-kjim-2018-382]\]. The inclusion criteria of the SPRINT study were individuals \> 50 years of age with at least one of the following: (1) history of clinical/subclinical CVD, excluding stroke; (2) Framingham risk score \> 15; (3) aged ≥ 75 years; or (4) CKD with estimated glomerular filtration rate between 20 to 60 mL/min/1.73 m2. However, as stated earlier, due to both the inclusion criteria and the method of office BP measurement, it is unclear whether the majority of the study population enrolled in the SPRINT study would have had SBP \> 140 mmHg if the baseline medications had been washed out and manual office BP measurement methods had been used for BP measurements \[[@b10-kjim-2018-382]\]. However, one finding of the SPRINT study was that further intensive lowering of BP in high-risk hypertensive patients was associated with decreased mortality and cardiovascular events. In addition, the potential benefits of intensive BP lowering in high-risk patients were demonstrated by Xie et al. \[[@b13-kjim-2018-382]\], in a meta-analysis of 19 clinical trials including 44,989 patients. In that meta-analysis, the average cardiovascular event rate was approximately 0.9% per year, corresponding to 9% to 10% per 10 years, and the average BP of the intensive BP lowering arm and the usual treatment arm was 133/76 and 140/81 mmHg, respectively \[[@b13-kjim-2018-382]\]. The results showed that intensive BP lowering was associated with a 14% reduction in cardiovascular events, 13% reduction in myocardial infarction, 22% reduction in stroke, 10% reduction in albuminuria, and 19% reduction in retinopathy progression without significant reduction in heart failure, cardiovascular death, total mortality, or end-stage renal disease \[[@b13-kjim-2018-382]\]. Based on this meta-analysis, the 2017 American guideline recommends drug treatment for primary prevention in high-risk stage 1 hypertensive patients with an arteriosclerotic cardiovascular disease (ASCVD) risk score ≥ 10%, and in all stage 1 hypertension patients with previous CVD. A recent meta-analysis by Brunstrom and Carlberg \[[@b14-kjim-2018-382]\] showed the association of antihypertensive treatment with a significant reduction in MACE, stroke, and heart failure in clinical trials that lowered BP in patients with a mean SBP of 138 mmHg and coronary heart disease. In addition, the aforementioned meta-analysis by Ettehad et al. \[[@b12-kjim-2018-382]\] revealed an association of BP lowering with reduced risk of major cardiovascular events, coronary heart disease, stroke, heart failure, and all-cause mortality in subjects with baseline SBP between 130 to 139 mmHg. In the same meta-analysis, BP lowering significantly reduced coronary heart disease in patients with baseline history of CVD whose baseline SBP was 139 mmHg, and significantly reduced the risk of heart failure in patients with baseline history of CVD and baseline SBP of 138 mmHg \[[@b12-kjim-2018-382]\]. Therefore, antihypertensive treatment is indicated for (1) secondary prevention of CVD in individuals with previous CVD, particularly coronary heart disease, and SBP between 130 to 139 mmHg; and (2) primary prevention of CVD in high-risk individuals with SBP between 130 to 139 mmHg.

Several lines of evidence suggest that the above findings should not be generalized to all individuals with SBP in the range of 130 to 139 mmHg. In the Heart Outcomes Prevention Evaluation 3 (HOPE-3) trial, 12,705 subjects at intermediate cardiovascular risk were randomized using a two-by-two design to receive Candesartan + hydrochlorothiazide, rosuvastatin or placebo \[[@b15-kjim-2018-382]\]. Although antihypertensive medications failed to significantly reduce the primary endpoints, participants in the upper tertile of baseline SBP (\> 143.5 mmHg) had significantly lower rates of first coprimary outcomes (defined as the composite of cardiovascular mortality, non-fatal myocardial infarction, and non-fatal stroke), and second coprimary outcomes (defined as the composite of coprimary outcomes, resuscitated cardiac arrest, heart failure, and revascularization). However, antihypertensive treatment showed no benefit in subjects in the middle and lower tertiles of baseline SBP \[[@b15-kjim-2018-382]\]. The results from the HOPE-3 study suggest that BP lowering with antihypertensive treatment does not prevent CVD in subjects with intermediate-to-low-risk CVD and SBP \< 140 mmHg. In a meta-analysis of BP treatment in individuals with high-normal and normal BP at baseline, subjects at high- to very-high cardiovascular risk derived benefit from antihypertensive treatment, with a 60% reduction in the risk of stroke (hazard ratio \[HR\], 0.40; 95% CI, 0.20 to 0.81). However, subjects with low-to-moderate risk of CVD had no significant reduction in stroke, coronary heart disease, heart failure, cardiovascular death, or all-cause mortality \[[@b16-kjim-2018-382]\]. In the aforementioned meta-analysis by Brunstrom and Carlberg \[[@b14-kjim-2018-382]\], 74 clinical trials including the data of 306,273 subjects were analyzed regarding the efficacy of antihypertensive treatment according to the baseline SBP. The results showed that antihypertensive treatment in patients with baseline SBP ≥ 160 mmHg was associated with a significant reduction in the risk of cardiovascular mortality, major cardiovascular events, coronary heart disease, stroke, and heart failure. Similarly, antihypertensive treatment in subjects with baseline SBP in the range of 140 to 159 mmHg was associated with a significant reduction in the risk of major cardiovascular events and coronary heart disease. However, antihypertensive treatment in subjects with baseline SBP \< 140 mmHg showed no association with reduced risk of cardiovascular mortality, major cardiovascular events, coronary heart disease, or stroke \[[@b14-kjim-2018-382]\].

Another important consideration in antihypertensive treatment is the risk of adverse events. A meta-analysis of 50 randomized clinical trials, which provided data on adverse events attributed to BP lowering treatment, showed that a 24% reduction in major cardiovascular risk factors was associated with an 89% increase in the risk of discontinuation, which corresponds to the prevention of 33 major cardiovascular events and 84 excess discontinuations/1,000 patients for 5 years \[[@b17-kjim-2018-382]\]. As such, the benefit of BP lowering in high-normal subjects should be considered with caution, and careful titration should be performed to minimize adverse events. In addition, excessive lowering of BP, particularly in patients at high risk of CAD, may increase mortality and cardiovascular events. In a pooled analysis of the ONTARGET and TRANSCEND trials, which included 30,937 subjects at high cardiovascular risk, treating SBP \< 120 mmHg was associated with increased risk of composite cardiovascular outcome (HR, 1.14; 95% CI, 1.03 to 1.26), cardiovascular death (HR, 1.29; 95% CI, 1.12 to 1.49), and all-cause death (HR, 1.28; 95% CI, 1.15 to 1.42) compared to treated subjects with SBP between 120 to 140 mmHg \[[@b18-kjim-2018-382]\]. Furthermore, a mean DBP \< 70 mmHg was associated with increased risks of composite primary outcome (HR, 1.31; 95% CI, 1.20 to 1.42), myocardial infarction (HR, 1.55; 95% CI, 1.33 to 1.80), hospitalization for heart failure (HR, 1.59; 95% CI, 1.36 to 1.86), and all-cause mortality (HR, 1.16; 95% CI, 1.06 to 1.28) compared to subjects with a mean DBP in the range of 70 to 80 mmHg \[[@b18-kjim-2018-382]\]. Based on these data, the 2018 European Society of Cardiology/European Society of Hypertension (ESC/ESH) guideline recommends that treated BP should not be lowered below 120/70 mmHg \[[@b2-kjim-2018-382]\]. This recommendation is supported by a recent analysis of 1,234,435 participants of the Korean Cancer Prevention Study cohort (789,255 males, aged 30 to 95 years) followed up for 22.5 million person-years. The study demonstrated that mortality from all-cause and ASCVD in those with DBP \< 60 mmHg compared to those with DBP between 70 to 79 mmHg showed HRs of 1.23 (95% CI, 1.16 to 1.30) and 1.37 (95% CI, 1.20 to 1.57), respectively \[[@b19-kjim-2018-382]\].

CONCLUSIONS
===========

The current evidence suggests that antihypertensive treatment may be beneficial for subjects with SBP between 130 to 139 mmHg, for primary prevention in those at high risk of CVD and secondary prevention for those with coronary heart disease. However, there is a narrow therapeutic window between 120 to 130/70 to 80 mmHg, below which there may be an increased risk of mortality and cardiovascular events. Therefore, careful titration of antihypertensive medications to lower SBP to 130 mmHg or below should be performed while ensuring that there are no adverse events. In addition, care should be taken to titrate the dosage to maintain the BP above 120/70 mmHg. No benefit of antihypertensive treatment for primary prevention has been shown in subjects with SBP below 140 mmHg at low to intermediate risk of CVD.
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